Startup aims for tailwind after Alzheimer's study involving Novo drug
![Kariya Pharmaceuticals CEO Ian Laquian | Photo: Kariya Pharmaceuticals PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article12551169.ece/ALTERNATES/schema-16_9/doc7d4zvkq1ybd17cl604hs.jpg)
This year's Alzheimer's conference, CTAD, has been particularly exhilarating to Kariya Pharma's Chief Science Officer Christian Hölscher.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Novo Nordisk acquires collaborative partner for USD 1.8bn
For subscribers